A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Matthieu Duchemin(Memorial Sloan Kettering Cancer Center), Sinchun Hwang(Memorial Sloan Kettering Cancer Center), William D. Tap(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Joseph P. Erinjeri(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Martina Bradić(New York University), Sujana Movva(Memorial Sloan Kettering Cancer Center), Mary Louise Keohan(Roche (Switzerland)), Kenneth Seier(Memorial Sloan Kettering Cancer Center), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Philip C. Wong(Johns Hopkins University), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Rhoena Desir(Memorial Sloan Kettering Cancer Center), Matthew D. Biniakewitz(Memorial Sloan Kettering Cancer Center), S Jasnani(Memorial Sloan Kettering Cancer Center), Li‐Xuan Qin(Memorial Sloan Kettering Cancer Center)
Cited by 6
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k